SUBSCRIBE
SUBSCRIBE

Madrigal Pharmaceuticals

NEWS
3 Biotechs That Got Huge Boosts From Spark's FDA P
Biotech Bay
8 Possible Biopharma Takeover Targets for 2018
The possibility of a tax bill being passed has many investors and analysts forecasting 2018 to be a big year for mergers and acquisitions.
December 18, 2017
 · 
5 min read
 · 
Mark Terry
Load More
JOBS
IN THE PRESS
Pharm Country
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - March 06, 2024
March 6, 2024
 · 
2 min read
Policy
Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis
March 5, 2024
 · 
9 min read
Business
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results
February 28, 2024
 · 
12 min read
Business
Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer
February 28, 2024
 · 
3 min read
Deals
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - February 21, 2024
February 21, 2024
 · 
1 min read
Drug Development
Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine
February 8, 2024
 · 
12 min read
Pharm Country
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - February 06, 2024
February 6, 2024
 · 
1 min read
Business
Madrigal Pharmaceuticals Announces Additions to Its Leadership Team
January 29, 2024
 · 
3 min read
Deals
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
January 22, 2024
 · 
1 min read
Pharm Country
Madrigal Pharmaceuticals Presents Five Health Economics Outcomes Research Abstracts at the NASH-TAG Annual Conference
January 4, 2024
 · 
11 min read
Load More